Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy
- PMID: 26306821
- PMCID: PMC4549373
- DOI: 10.3402/pba.v5.28743
Rapamycin improves motor function, reduces 4-hydroxynonenal adducted protein in brain, and attenuates synaptic injury in a mouse model of synucleinopathy
Abstract
Background: Synucleinopathy is any of a group of age-related neurodegenerative disorders including Parkinson's disease, multiple system atrophy, and dementia with Lewy Bodies, which is characterized by α-synuclein inclusions and parkinsonian motor deficits affecting millions of patients worldwide. But there is no cure at present for synucleinopathy. Rapamycin has been shown to be neuroprotective in several in vitro and in vivo synucleinopathy models. However, there are no reports on the long-term effects of RAPA on motor function or measures of neurodegeneration in models of synucleinopathy.
Methods: We determined whether long-term feeding a rapamycin diet (14 ppm in diet; 2.25 mg/kg body weight/day) improves motor function in neuronal A53T α-synuclein transgenic mice (TG) and explored underlying mechanisms using a variety of behavioral and biochemical approaches.
Results: After 24 weeks of treatment, rapamycin improved performance on the forepaw stepping adjustment test, accelerating rotarod and pole test. Rapamycin did not alter A53T α-synuclein content. There was no effect of rapamycin treatment on midbrain or striatal monoamines or their metabolites. Proteins adducted to the lipid peroxidation product 4-hydroxynonenal were decreased in brain regions of both wild-type and TG mice treated with rapamycin. Reduced levels of the presynaptic marker synaptophysin were found in several brain regions of TG mice. Rapamycin attenuated the loss of synaptophysin protein in the affected brain regions. Rapamycin also attenuated the loss of synaptophysin protein and prevented the decrease of neurite length in SH-SY5Y cells treated with 4-hydroxynonenal.
Conclusion: Taken together, these data suggest that rapamycin, an FDA approved drug, may prove useful in the treatment of synucleinopathy.
Keywords: 4-hydroxynonenal (4-HNE); motor function; rapamycin; synaptic injury; synaptophysin; synucleinopathy.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4549373/bin/PBA-5-28743-g001.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4549373/bin/PBA-5-28743-g002.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4549373/bin/PBA-5-28743-g003.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4549373/bin/PBA-5-28743-g004.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4549373/bin/PBA-5-28743-g005.gif)
Similar articles
-
Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.Exp Neurol. 2018 Jan;299(Pt A):172-196. doi: 10.1016/j.expneurol.2017.10.017. Epub 2017 Oct 19. Exp Neurol. 2018. PMID: 29056362 Free PMC article.
-
Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.Pharmacol Res. 2019 Dec;150:104538. doi: 10.1016/j.phrs.2019.104538. Epub 2019 Nov 9. Pharmacol Res. 2019. PMID: 31707034
-
Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathy.Transl Neurodegener. 2022 Jul 1;11(1):34. doi: 10.1186/s40035-022-00309-x. Transl Neurodegener. 2022. PMID: 35773715 Free PMC article.
-
Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy.Acta Neuropathol Commun. 2020 Aug 28;8(1):150. doi: 10.1186/s40478-020-01026-0. Acta Neuropathol Commun. 2020. PMID: 32859276 Free PMC article.
-
Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery.Cells. 2019 Jun 9;8(6):565. doi: 10.3390/cells8060565. Cells. 2019. PMID: 31181865 Free PMC article. Review.
Cited by
-
To re-examine the intersection of microglial activation and neuroinflammation in neurodegenerative diseases from the perspective of pyroptosis.Front Aging Neurosci. 2023 Nov 9;15:1284214. doi: 10.3389/fnagi.2023.1284214. eCollection 2023. Front Aging Neurosci. 2023. PMID: 38020781 Free PMC article. Review.
-
Neural stem cells transplantation combined with ethyl stearate improve PD rats motor behavior by promoting NSCs migration and differentiation.CNS Neurosci Ther. 2023 Jun;29(6):1571-1584. doi: 10.1111/cns.14119. Epub 2023 Mar 16. CNS Neurosci Ther. 2023. PMID: 36924304 Free PMC article.
-
Pathogenic Aspects and Therapeutic Avenues of Autophagy in Parkinson's Disease.Cells. 2023 Feb 15;12(4):621. doi: 10.3390/cells12040621. Cells. 2023. PMID: 36831288 Free PMC article. Review.
-
The role of the endolysosomal pathway in α-synuclein pathogenesis in Parkinson's disease.Front Cell Neurosci. 2023 Jan 10;16:1081426. doi: 10.3389/fncel.2022.1081426. eCollection 2022. Front Cell Neurosci. 2023. PMID: 36704248 Free PMC article. Review.
-
Targeting protein clearance pathways in GBA1-associated Parkinson disease.Expert Opin Ther Targets. 2022 Dec;26(12):1031-1035. doi: 10.1080/14728222.2022.2166828. Epub 2023 Jan 12. Expert Opin Ther Targets. 2022. PMID: 36628605 Free PMC article. No abstract available.
References
-
- Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci. 2000;920:16–27. - PubMed
-
- Ravikumar B, Berger Z, Vacher C, O'Kane CJ, Rubinsztein DC. Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet. 2006;15:1209–16. - PubMed
-
- Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC. Alpha-synuclein is degraded by both autophagy and the proteasome. J Biol Chem. 2003;278:25009–13. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous